CO5560578A2 - Derivados de quinazolina como inhibidores de src tirosina cinasa - Google Patents

Derivados de quinazolina como inhibidores de src tirosina cinasa

Info

Publication number
CO5560578A2
CO5560578A2 CO05042313A CO05042313A CO5560578A2 CO 5560578 A2 CO5560578 A2 CO 5560578A2 CO 05042313 A CO05042313 A CO 05042313A CO 05042313 A CO05042313 A CO 05042313A CO 5560578 A2 CO5560578 A2 CO 5560578A2
Authority
CO
Colombia
Prior art keywords
alkyl
group
carbamoyl
alkylamino
hydrogen
Prior art date
Application number
CO05042313A
Other languages
English (en)
Spanish (es)
Inventor
Patrick Ple
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO5560578A2 publication Critical patent/CO5560578A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CO05042313A 2002-11-04 2005-05-03 Derivados de quinazolina como inhibidores de src tirosina cinasa CO5560578A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02292736 2002-11-04
EP03290900 2003-04-10

Publications (1)

Publication Number Publication Date
CO5560578A2 true CO5560578A2 (es) 2005-09-30

Family

ID=32313852

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05042313A CO5560578A2 (es) 2002-11-04 2005-05-03 Derivados de quinazolina como inhibidores de src tirosina cinasa

Country Status (27)

Country Link
US (1) US7462623B2 (cg-RX-API-DMAC7.html)
EP (1) EP1562955B1 (cg-RX-API-DMAC7.html)
JP (2) JP4593464B2 (cg-RX-API-DMAC7.html)
KR (1) KR101089462B1 (cg-RX-API-DMAC7.html)
AR (1) AR041884A1 (cg-RX-API-DMAC7.html)
AT (1) ATE387451T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003278383B2 (cg-RX-API-DMAC7.html)
BR (1) BR0315756A (cg-RX-API-DMAC7.html)
CA (1) CA2503371C (cg-RX-API-DMAC7.html)
CO (1) CO5560578A2 (cg-RX-API-DMAC7.html)
CY (1) CY1108061T1 (cg-RX-API-DMAC7.html)
DE (1) DE60319410T2 (cg-RX-API-DMAC7.html)
DK (1) DK1562955T3 (cg-RX-API-DMAC7.html)
EG (1) EG24957A (cg-RX-API-DMAC7.html)
ES (1) ES2300619T3 (cg-RX-API-DMAC7.html)
IL (1) IL168013A (cg-RX-API-DMAC7.html)
IS (1) IS2568B (cg-RX-API-DMAC7.html)
MX (1) MXPA05004858A (cg-RX-API-DMAC7.html)
MY (1) MY137835A (cg-RX-API-DMAC7.html)
NO (1) NO331951B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ539408A (cg-RX-API-DMAC7.html)
PL (1) PL215161B1 (cg-RX-API-DMAC7.html)
PT (1) PT1562955E (cg-RX-API-DMAC7.html)
RU (1) RU2350618C2 (cg-RX-API-DMAC7.html)
SI (1) SI1562955T1 (cg-RX-API-DMAC7.html)
TW (1) TWI320786B (cg-RX-API-DMAC7.html)
WO (1) WO2004041829A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0406445D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
GB0427697D0 (en) * 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
NZ556673A (en) * 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE045810T2 (hu) 2010-09-27 2020-01-28 Exelixis Inc MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
WO2020055755A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
CN119504612B (zh) * 2024-11-18 2026-04-07 中国海洋大学 一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
GB9205320D0 (en) * 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) * 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0888310B1 (en) * 1996-03-15 2005-09-07 AstraZeneca AB Cinnoline derivatives and use as medicine
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1252054C (zh) 1996-09-25 2006-04-19 曾尼卡有限公司 抑制生长因子的作用的喹啉衍生物
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
CZ303899B6 (cs) 1998-09-29 2013-06-19 Wyeth Holdings Corporation Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
ES2241324T3 (es) 1998-10-08 2005-10-16 Astrazeneca Ab Derivados de quinazolina.
EE05345B1 (et) * 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
HK1046688A1 (zh) 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
GB9922171D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
PT1244647E (pt) * 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
IL151626A0 (en) 2000-04-07 2003-04-10 Astrazeneca Ab Quinazoline compounds
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153805A0 (en) * 2000-08-09 2003-07-31 Astrazeneca Ab Cinnoline compounds
US20030207878A1 (en) 2000-08-09 2003-11-06 Hennequin Lawrent Francois Andre Chemical compounds
WO2002012226A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
AU2001278609B2 (en) * 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
WO2002030924A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en) 2000-10-13 2002-04-18 Astrazeneca Ab Quinazoline derivatives
US20040063733A1 (en) 2000-10-25 2004-04-01 Lambert Christine Marie Paul Quinazoline derivatives
ATE409185T1 (de) * 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
WO2002092579A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab 4-anilinoquinazoline derivatives
WO2002092578A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
WO2002092577A1 (en) 2001-05-14 2002-11-21 Astrazeneca Ab Quinazoline derivatives
ES2272737T3 (es) 2001-07-16 2007-05-01 Astrazeneca Ab Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
AU2002365664A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives as antitumour agents
EP2292615A1 (en) * 2002-02-01 2011-03-09 AstraZeneca AB Quinazoline compounds
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1528925B1 (en) 2002-07-09 2009-04-22 Astrazeneca AB Quinazoline derivatives for use in the treatment of cancer
AU2003249000B2 (en) 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
DE602004032310D1 (de) 2003-02-13 2011-06-01 Astrazeneca Ab Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
US20060122199A1 (en) 2006-06-08
IL168013A (en) 2013-03-24
SI1562955T1 (sl) 2008-06-30
PL376255A1 (en) 2005-12-27
IS2568B (is) 2010-01-15
JP2010270143A (ja) 2010-12-02
RU2005117337A (ru) 2006-01-20
NO20051900L (no) 2005-06-01
PT1562955E (pt) 2008-05-05
HK1079195A1 (en) 2006-03-31
CA2503371C (en) 2011-01-11
PL215161B1 (pl) 2013-10-31
JP4593464B2 (ja) 2010-12-08
RU2350618C2 (ru) 2009-03-27
NZ539408A (en) 2007-09-28
CY1108061T1 (el) 2014-02-12
JP2006506463A (ja) 2006-02-23
CA2503371A1 (en) 2004-05-21
TWI320786B (en) 2010-02-21
NO331951B1 (no) 2012-05-14
MY137835A (en) 2009-03-31
TW200420567A (en) 2004-10-16
ATE387451T1 (de) 2008-03-15
BR0315756A (pt) 2005-09-06
AU2003278383A1 (en) 2004-06-07
EG24957A (en) 2011-02-28
DK1562955T3 (da) 2008-06-02
EP1562955A1 (en) 2005-08-17
KR101089462B1 (ko) 2011-12-07
KR20050074526A (ko) 2005-07-18
AR041884A1 (es) 2005-06-01
AU2003278383B2 (en) 2007-06-14
US7462623B2 (en) 2008-12-09
EP1562955B1 (en) 2008-02-27
ES2300619T3 (es) 2008-06-16
DE60319410T2 (de) 2009-02-19
MXPA05004858A (es) 2005-07-22
IS7849A (is) 2005-05-19
DE60319410D1 (en) 2008-04-10
WO2004041829A1 (en) 2004-05-21

Similar Documents

Publication Publication Date Title
CO5580775A2 (es) Derivados de quinazolina como agentes antineoplasicos
CO5580774A2 (es) Derivados de quinazolina como agentes antineoplasicos
CO5690594A2 (es) Derivados de quinazolina como inhibidores de tirosina cinasa
CO5680435A2 (es) Derivados de quinazolina inhibidores de tirosina quinasa erbb y egb, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
ATE407679T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
DE602004026047D1 (de) Hemmer der akt aktivität
AR041189A1 (es) Piridinas y pirimidinas condensadas con actividad anti-angiogenica, que actuan sobre el receptor de tirosina quinasa
WO2004096130A3 (en) Inhibitors of akt activity
ATE428427T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
DE602004023838D1 (de) Hemmer der akt aktivität
AR033560A1 (es) Derivados de quinazolina, proceso para su preparacion, composicion farmaceutica, y su uso en la fabricacion de un medicamento,
MXPA04006614A (es) Deazapurinas y usos de las mismas.
AR049294A1 (es) DERIVADOS DE QUINAZOLINA; INHIBIDORES DE LA TIROSINA QUINASA DEL RECEPTOR ERBB2; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN; MÉTODOS PARA SU PREPARACIoN Y SU USO COMO MEDICAMENTO PARA EL TRATAMIENTO O PREVENCIoN DE TUMORES SoLIDOS.
PE20010306A1 (es) Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
ATE503483T1 (de) Hemmer der akt aktivität
SG154434A1 (en) Quinazolinone derivatives as parp inhibitors
RU2008145708A (ru) Агонисты аденозинового рецептора a3
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
WO2004058721A3 (en) Pyrazole derivatives modulators of hepatocyte growth factor (scatter factor) activity
PT1210320E (pt) Aminobenzofenonas como inibidores de il-1beta e tnf-alfa
JP2006515593A5 (cg-RX-API-DMAC7.html)
RU2007148412A (ru) 6,7-ненасыщенное 7-карбамоилзамещенное производное морфинана
AR041884A1 (es) Derivados de quinazolina
AR052315A1 (es) Derivados de quinazolina utiles para el tratamiento de cancer
AR025068A1 (es) Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis

Legal Events

Date Code Title Description
FC Application refused